Cancer clinical trials advance treatment paradigms by testing agents for potentially greater efficacy or lesser toxicity. The Research Pharmacy shared resource provides expertise in investigational and commercially available cancer therapeutic agents and ensures a uniformly high standard of safe, accurate treatment for CINJ patients with cancer participating in clinical trials; these services are crucial to one of the central strategic initiatives of the cancer center: high quality, innovative translational research. The Research Pharmacy shared resource of Rutgers Cancer Institute of New Jersey (CINJ) is a Cancer Center managed shared resource whose purpose is to support CINJ members who conduct rigorously reviewed research with investigational agents in human subjects by providing an efficient, centralized service of extraordinary quality. Since the last CCSG submission, Research Pharmacy is increasingly called upon for consultation in the planning of clinical projects. CINJ investigators seek advice on issues regarding drug interactions, drug sequencing for multi-agent trials, dose modifications, formulation of compounds, identification of compounds for use, and consultations regarding Investigational New Drug (IND) applications. Additionally, our Informatics Pharmacist performs various data mining of our electronic medical record (EMR) to assist investigators in selecting and modeling clinical trials based on our patient population. These efforts are guided by policies and procedures ensuring compliance with HIPAA and institutional review board (IRB) requirements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA072720-20
Application #
9632902
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-07
Budget End
2020-02-29
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Farber, Nicholas J; Radadia, Kushan D; Singer, Eric A (2018) Accuracy of Nodal Staging and Outcomes of Lymphadenectomy for Non-metastatic Renal Cell Carcinoma: An Analysis of the National Cancer Database. Bladder Cancer 4:S14-S15
Poillet-Perez, Laura; Xie, Xiaoqi; Zhan, Le et al. (2018) Autophagy maintains tumour growth through circulating arginine. Nature 563:569-573
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803

Showing the most recent 10 out of 775 publications